Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and structure-activity relationship of the isoindolinyl benzisoxazolpiperidines as potent, selective, and orally active human dopamine D4 receptor antagonists.
Hendrix JA, Shimshock SJ, Shutske GM, Tomer JD 4th, Kapples KJ, Palermo MG, Corbett TJ, Vargas HM, Kafka S, Brooks KM, Laws-Ricker L, Lee DK, de Lannoy I, Bordeleau M, Rizkalla G, Owolabi J, Kamboj RK. Hendrix JA, et al. Among authors: kafka s. Chembiochem. 2002 Oct 4;3(10):999-1009. doi: 10.1002/1439-7633(20021004)3:10<999::AID-CBIC999>3.0.CO;2-A. Chembiochem. 2002. PMID: 12362366
Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Hrib NJ, Jurcak JG, Bregna DE, Burgher KL, Hartman HB, Kafka S, Kerman LL, Kongsamut S, Roehr JE, Szewczak MR, Woods-Kettelberger AT, Corbett R. Hrib NJ, et al. Among authors: kafka s. J Med Chem. 1996 Sep 27;39(20):4044-57. doi: 10.1021/jm960268u. J Med Chem. 1996. PMID: 8831770
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.
Connelly K, Eades LE, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, Gregory K, Brunner H, Burke L, Arnaud L, Askanase A, Aranow C, Vital E, Pons-Estel G, Dantata K, Andersen J, Cornet A, Buie J, Sun Y, Tanaka Y, Simon L, Lahoud Y, Friedman A, Kalunian K, Zuraw Q, Werth V, Garces S, Morand EF; TRM-SLE Consortium. Connelly K, et al. Nat Rev Rheumatol. 2023 Sep;19(9):592-602. doi: 10.1038/s41584-023-00993-7. Epub 2023 Jul 11. Nat Rev Rheumatol. 2023. PMID: 37433880 Review.
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.
Curtis JR, Chakravarty SD, Black S, Kafka S, Xu S, Langholff W, Parenti D, Greenspan A, Schwartzman S. Curtis JR, et al. Among authors: kafka s. Rheumatol Ther. 2021 Dec;8(4):1551-1563. doi: 10.1007/s40744-021-00354-4. Epub 2021 Aug 20. Rheumatol Ther. 2021. PMID: 34417735 Free PMC article.
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB. Rahman P, et al. Among authors: kafka s. J Rheumatol. 2021 Dec;48(12):1815-1823. doi: 10.3899/jrheum.201532. Epub 2021 May 1. J Rheumatol. 2021. PMID: 33934076 Free article. Clinical Trial.
58 results